Most marine-derived compounds possess a few defining characteristics. First, often very low doses are given to patients, and they are administered almost exclusively via intravenous infusion (i.v.). The compounds are typically large molecules, especially the depsipeptides, and they are often hydrophobic. These attributes make them fascinating compounds in terms of pharmacokinetics but also from a bioanalytical point of view.
The first marine-derived compound approved by the United States (US) Food and Drug Administration (FDA) was cytarabine (Cytosar U®) in 1969, followed by trabectedin (Yondelis®),eribulin mesylate (Halaven®), brentuximab vedotin (Adcetris®), and midostaurin (Rydapt®) in the years 2007, 2010, 2011, 2013, and 2017, respectively.
Scope of the Report:
The classification of Marine Derived Drugs includes mollusk sources, Sponge sources, tunicate sources, fish sources and others. And the proportion of mollusk sources is occupied 49.40% of global revenue market share in 2018.
North America is the largest consumption place, with a consumption market share nearly 50.55% in 2018. Following Europe, Europe is the second largest consumption place with the consumption market share of 29.87%.
The worldwide market for Marine Derived Drugs is expected to grow at a CAGR of roughly 8.4% over the next five years, will reach 2570.5 million US$ in 2024, from 1718 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Marine Derived Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Seattle Genetics
Eisai Co
Tekada
Pfizer
Pharma Mar
Johnson and Johnson
GSK
TerSera Therapeutics
Teva
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Mollusk
Sponge
Tunicate
Fish
Others
Market Segment by Applications, can be divided into
Antitumor Drugs
Anti-Cardiovascular Drugs
Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Marine Derived Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Marine Derived Drugs, with price, sales, revenue and global market share of Marine Derived Drugs in 2017 and 2018.
Chapter 3, the Marine Derived Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Marine Derived Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Marine Derived Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Marine Derived Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Summary:
Get latest Market Research Reports on Marine Derived Drugs . Industry analysis & Market Report on Marine Derived Drugs is a syndicated market report, published as Global Marine Derived Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Marine Derived Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.